Safety and efficacy of tenecteplase in acute myocardial infarction

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 5, 2003, Pages 791-798

  Guerra, Daniel R ^a   Karha, Juhana ^a   Gibson, C Michael ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b TIMI Data Coordinating Center   (United States)

Author keywords

Acute myocardial infarction; Tenecteplase

Indexed keywords

ABCIXIMAB; ALTEPLASE; ENOXAPARIN; FIBRIN; FIBRINOLYTIC AGENT; HEPARIN; LANOTEPLASE; LOW MOLECULAR WEIGHT HEPARIN; RETEPLASE; STREPTOKINASE; TENECTEPLASE;

ACUTE HEART INFARCTION; AGE DISTRIBUTION; BLEEDING; BODY WEIGHT; BRAIN HEMORRHAGE; CLINICAL TRIAL; CORONARY ARTERY DILATATION; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SPECIFICITY; HEART DISEASE; HUMAN; MORTALITY; PHARMACODYNAMICS; REVIEW; STROKE; TREATMENT OUTCOME;

AREA UNDER CURVE; BODY WEIGHT; EXPERT TESTIMONY; FIBRINOLYTIC AGENTS; HALF-LIFE; HUMANS; METABOLIC CLEARANCE RATE; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; SAFETY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0038446754     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.5.791     Document Type: Review

References (45)

1. BRAUNWALD E: The open artery theory is alive and well again. N. Engl. J. Med. (1993) 329:1650-1652.
2. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N. Engl. J. Med. (1993) 329:1615-1622.
3. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. GUSTO IIb investigators. N. Engl. J. Med. (1997) 336:1621-1628.
4. GRINES CL, BROWNE KF, MARCO J et al.: A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N. Engl. J. Med. (1993) 328:673-679.
5. DE BOER MJ, HOORNTJE JC, OTTERVANGER JP, REIFFERS S, SURYAPRANATA H: Immediate coronary angioplasty versus intravenous streptokinase in acute myocardial infarction: left ventricular ejection fraction, hospital mortality and reinfarction. J. Am. Coll. Cardiol. (1994) 23:1004-1008.
6. WEAVER WD, SIMES RJ, BETRIU A et al.: Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA (1997) 278:2093-2098.
7. RYAN TJ, ANTMAN EM, BROOKS NH et al.: 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J. Am. Coll. Cardiol. (1999) 34:890-911.
8. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet (1994) 343:311-322.
9. BERKOWITZ SD, GRANGER CB, PIEPER KS et al.: Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction: The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded coronary arteries (GUSTO) I investigators. Circulation (1997) 95:2508-2516.
10. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N. Engl. J. Med. (1993) 329:673-682.
11. LLEVADOT J, GIUGLIANO RP, ANTMAN EM: Bolus fibrinolytic therapy in acute myocardial infarction. JAMA (2001) 286:442-449.
12. KEYT BA, PAONI NF, REFINO CJ et al.: A faster-acting and more potent form of tissue plasminogen activator. Proc. Natl. Acad. Sci. USA (1994) 91:3670-3674.
13. PAONI NF, KEYT BA, REFINO CJ et al.: A slow clearing, fibrin-specific, PAI-1 resistant variant of tPA (T103N, KHRR 296-299 AAAA). Thromb. Haemost. (1993) 70:307-312.
14. GIBSON CM, MARBLE SJ: Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA). Clin. Cardiol. (2001) 24:577-584.
15. BENEDICT CR, REFINO CJ, KEYT BA et al.: New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation (1995) 92:3032-3040.
16. CANNON CP, MCCABE CH, GIBSON CM et al.: TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation (1997) 95:351-356.
17. MUELLER HS, RAO AK, FORMAN SA: Thrombolysis In Myocardial Infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. J. Am. Coll. Cardiol. (1987) 10:479-490.
18. VANDESCHUEREN S, BARRIOS L, KERDSINCHAI P et al.: A recombinant trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation (1995) 92:2044-2049.
19. MODI NB, FOX NL, CLOW FW et al.: Pharmacokinetics and pharmacodynamics of tenecteplase: results from a Phase II study in patients with acute myocardial infarction. J. Clin. Pharmacol. (2000) 40:508-515.
20. CANNON CP, GIBSON CM, MCCABE CH et al.: TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation (1998) 98:2805-2814.
21. GIUGLIANO RP, CANNON CP, MCCABE CH, VAN DE WERF F, BRAUNWALD E: Lower-dose heparin with thrombolysis is associated with lower rates of intracranial hemorrhage: results from TIMI 10B and ASSENT 1. Circulation (1997) 96:1-535.
22. GIBSON CM, CANNON CP, MURPHY SA et al.: Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators. Am. J. Cardiol. (1999) 84:976-980.
23. GIBSON CM, MURPHY SA, RIZZO MJ et al.: Relationship between TIMI frame Count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation (1999) 99:1945-1950.
24. WANG-CLOW F, FOX NL, CANNON CP et al.: Determination of a weight-adjusted dose of TNK-tissue plasminogen activator. Am. Heart. J. (2001) 141:33-40.
25. GIBSON CM, CANNON CP, MURPHY SA, MARBLE SJ, BARRON HV, BRAUNWALD E: Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation (2002) 105:1909-1913.
26. VAN DE WERF F, CANNON CP, LUYTEN A et al.: Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am. Heart J. (1999) 137:786-791.
27. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet (1999) 354:716-722.
28. A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open occluded Coronary Arteries (GUSTO III) Investigators. N. Engl. J. Med. (1997) 337:1118-1123.
29. CANNON CP: Thrombolysis medication errors: benefits of bolus thrombolytic agents. Am. J. Cardiol. (2000) 85:17C-22C.
30. ALEXANDER J, LI X, CHIN R: Safety and efficacy of 50 mg of TNK-tPA in patients with acute myocardial infarction: results from ASSENT-2. Circulation (2000) 102:II-258.
31. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet (2001) 358:605-613.
32. ANTMAN EM, LOUWERENBURG HW, BAARS HF et al.: Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 trial. Circulation (2002) 105:1642-1649.
33. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. The European Myocardial Infarction Project Group. N. Engl. J. Med. (1993) 329:383-389.
34. RAWLES J, FOR THE GREAT GROUP: Halving of mortality at one year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). J. Am. Coll. Cardiol. (1994) 23:1-5.
35. WALLENTIN L: The ASSENT-3 prehospitalization satellite study, presented on behalf of ASSENT-3 PLUS investigators. 75th Scientific Sessions of the American Heart Association, Chicago, USA (2002).
36. ARMSTRONG PW, GRANGER C, VAN DE WERF F: Bolus fibrinolysis: risk, benefit, and opportunities. Circulation (2001) 103:1171-1173.
37. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International joint Efficacy Comparison of Thrombolytics. Lancet (1995) 346:329-336.
38. GURWITZ JH, GORE JM, GOLDBERG RJ et al.: Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann. Intern. Med. (1998) 129:597-604.
39. VAN DE WERF F, BARRON HV, ARMSTRONG PW et al.: Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur. Heart J. (2001) 22:2253-2261.
40. THIEMANN DR, CORESH J, SCHULMAN SP, GERSTENBLITH G: Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation (2000) 101:2239-2246.
41. AYANIAN JZ, BRAUNWALD E: Thrombolytic therapy for patients with myocardial infarction who are older than 75 years: do the risks outweigh the benefits? Circulation (2000) 101:2224.
42. ANTMAN EM, WILCOX RG, GIUGLIANO RP et al.: Long-Term comparison of lanoteplase and alteplase in ST elevation myocardial infarction: 6 Month follow-up in the TIME-II trial. Circulation (1999) 100:1-498.
43. MURPHY SA, GIBSON CM, VAN DE WERF F: Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT-1). Am. J. Cardiol. (2002) 90:51-54.
44. GIBSON CM: Weight-adjusted dosing of fibrinolytic agents. The good and the bad. 73rd Scientific Sessions of the American Heart Association, New Orleans, USA (2000).
45. ANGEJA BG, ALEXANDER JH, CHIN R et al.: Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial. Am. J. Cardiol. (2001) 88:1240-1245.